The FDA indicated that it intends to reschedule the meeting as soon as it can determine a schedule that will allow them to reconvene the advisory panel.
This meeting is an open public forum for the presentation and discussion of safety and efficacy information contained in the pixantrone NDA, for the treatment of relapsed/refractory aggressive non-hodgkin's lymphoma (NHL).
According to its usual practice, FDA has posted on its website briefing documents for the ODAC meeting that will be held to discuss the pixantrone NDA.
James Bianco, CEO of Cell Therapeutics, said: "We are pleased with the time that the FDA has invested in connection with its review of our application for pixantrone. We believe that many of the key issues they identified are addressed in our own briefing material which is now publically available as well.
"We are disappointed that the meeting was not able to take place as originally scheduled but understand that the severe weather conditions made travel safety an issue. We look forward to the ODAC meeting where our lymphoma expert physicians will discuss the clinical benefits of pixantrone with the advisory panel."